Harvard Bioscience, Inc. (NASDAQ:HBIO) Position Increased by Dalton Greiner Hartman Maher & Co.

Dalton Greiner Hartman Maher & Co. increased its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 14.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,573,981 shares of the medical instruments supplier’s stock after purchasing an additional 200,463 shares during the period. Dalton Greiner Hartman Maher & Co.’s holdings in Harvard Bioscience were worth $4,801,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in HBIO. Millennium Management LLC lifted its holdings in Harvard Bioscience by 982.2% during the 3rd quarter. Millennium Management LLC now owns 645,331 shares of the medical instruments supplier’s stock worth $1,984,000 after buying an additional 585,701 shares in the last quarter. Engine Capital Management LP lifted its holdings in Harvard Bioscience by 89.7% during the 3rd quarter. Engine Capital Management LP now owns 3,542,852 shares of the medical instruments supplier’s stock worth $10,536,000 after buying an additional 1,674,804 shares in the last quarter. Granahan Investment Management Inc. MA lifted its holdings in Harvard Bioscience by 91.8% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 1,771,964 shares of the medical instruments supplier’s stock worth $5,449,000 after buying an additional 848,191 shares in the last quarter. Monarch Partners Asset Management LLC lifted its holdings in Harvard Bioscience by 13.4% during the 3rd quarter. Monarch Partners Asset Management LLC now owns 123,470 shares of the medical instruments supplier’s stock worth $380,000 after buying an additional 14,630 shares in the last quarter. Finally, Wedge Capital Management L L P NC acquired a new position in Harvard Bioscience during the 3rd quarter worth $1,071,000. 64.31% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:HBIO opened at $3.14 on Thursday. The stock’s fifty day moving average price is $2.98 and its two-hundred day moving average price is $2.71. Harvard Bioscience, Inc. has a 52-week low of $1.51 and a 52-week high of $4.66. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.31 and a current ratio of 2.41. The company has a market cap of $120.67 million, a price-to-earnings ratio of 31.70 and a beta of 1.52.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). Harvard Bioscience had a positive return on equity of 5.22% and a negative net margin of 2.45%. The firm had revenue of $27.42 million for the quarter, compared to analyst estimates of $28.50 million. On average, equities analysts predict that Harvard Bioscience, Inc. will post 0.12 EPS for the current fiscal year.

Several research analysts have issued reports on HBIO shares. ValuEngine downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Tuesday, October 22nd. Benchmark downgraded Harvard Bioscience to a “buy” rating in a report on Monday, December 9th. Finally, Zacks Investment Research downgraded Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Wednesday, January 8th.

In related news, Director Bertrand Loy purchased 12,855 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were bought at an average price of $2.59 per share, with a total value of $33,294.45. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Value Fund Lp Palogic purchased 66,868 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was bought at an average cost of $1.29 per share, for a total transaction of $86,259.72. In the last three months, insiders bought 102,439 shares of company stock worth $178,492. 5.40% of the stock is currently owned by company insiders.

About Harvard Bioscience

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

Featured Story: Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).

Institutional Ownership by Quarter for Harvard Bioscience (NASDAQ:HBIO)

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.